Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis

被引:7
|
作者
Fan, Caibin [1 ]
Lu, Wei [2 ]
Li, Kai [1 ]
Zhao, Chunchun [1 ]
Wang, Fei [1 ]
Ding, Guanxiong [3 ]
Wang, Jianqing [1 ]
机构
[1] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch,Dept Urol, 26 Daoqian Rd, Suzhou 215000, Jiangsu, Peoples R China
[2] Suzhou Vocat Hlth Coll, Sch Nursing, Suzhou, Jiangsu, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune infiltration; metastatic castration resistant prostate cancer (mCRPC); RNA sequencing; bioinformatics analysis; immunotherapy; DIFFERENTIAL EXPRESSION ANALYSIS; BREAST-CANCER; IMMUNOTHERAPY; SURVIVAL; INTERLEUKIN-2; PROLIFERATION; ENZALUTAMIDE; ANTAGONISTS; INHIBITION; DIAGNOSIS;
D O I
10.3233/CBM-203222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage of prostate cancer and the main cause of morbidity and mortality, which is also a potential target for immunotherapy. METHOD: In this study, using the Approximate Relative Subset of RNA Transcripts (CIBERSORT) online method, we analysed the immune cell abundance ratio of each sample in the mCRPC dataset. The EdgeR (an R package) was used to classify differentially expressed genes (DEGs). Using the Database for annotation, visualisation and interactive exploration (DAVID) online method, we performed functional enrichment analyses. STRING online database and Cytoscape tools have been used to analyse protein-protein interaction (PPI) and classify hub genes. RESULTS: The profiles of immune infiltration in mCRPC showed that Macrophages M2, Macrophages M0, T cells CD4 memory resting, T cells CD8 and Plasma cells were the main infiltration cell types in mCRPC samples. Macrophage M0 and T cell CD4 memory resting abundance ratios were correlated with clinical outcomes. We identified 1102 differentially expressed genes (DEGs) associated with the above two immune cells to further explore the underlying mechanisms. Enrichment analysis found that DEGs were substantially enriched in immune response, cell metastasis, and metabolism related categories. We identified 20 hub genes by the protein-protein interaction network analysis. Further analysis showed that three critical hub genes, CCR5, COL1A1 and CXCR3, were significantly associated with prostate cancer prognosis. CONCLUSION: Our findings revealed the pattern of immune cell infiltration in mCRPC, and identified the types and genes of immune cells correlated with clinical outcomes. A new theoretical basis for immunotherapy may be given by our results.
引用
收藏
页码:363 / 377
页数:15
相关论文
共 50 条
  • [1] Identification of Core Genes and Potential Drugs for Castration-Resistant Prostate Cancer Based on Bioinformatics Analysis
    Liang, Xiao
    Hu, Kebang
    Li, Dawei
    Wang, Yanbo
    Liu, Min
    Wang, Xiaoxue
    Zhu, Wanying
    Wang, Xinyu
    Yang, Zixuan
    Lu, Ji
    DNA AND CELL BIOLOGY, 2020, 39 (05) : 836 - 847
  • [2] Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
    de la Maza, Maria Dolores Fenor
    Chandran, Khobe
    Rekowski, Jan
    Shui, Irene M.
    Gurel, Bora
    Cross, Emily
    Carreira, Suzanne
    Yuan, Wei
    Westaby, Daniel
    Miranda, Susana
    Ferreira, Ana
    Seed, George
    Crespo, Mateus
    Figueiredo, Ines
    Bertan, Claudia
    Gil, Veronica
    Riisnaes, Ruth
    Sharp, Adam
    Rodrigues, Daniel Nava
    Rescigno, Pasquale
    Tunariu, Nina
    Liu, Xiao Qiao
    Cristescu, Razvan
    Schloss, Charles
    Yap, Christina
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 659 - 667
  • [3] Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors
    Pavlov, A. Yu.
    Dzidzaria, A. G.
    Gafanov, R. A.
    Samusevich, V. A.
    Mirzoev, E. E.
    Kortyshkova, A. O.
    Aivazov, M. T.
    Mirzoev, F. E.
    ONKOUROLOGIYA, 2024, 20 (01): : 153 - 163
  • [4] Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
    El-Amm, Joelle
    Patel, Nihar
    Freeman, Ashley
    Aragon-Ching, Jeanny B.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 235 - 245
  • [5] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [6] Identification of marker genes and cell subtypes in castration-resistant prostate cancer cells
    Lin, Xiao-Dan
    Lin, Ning
    Lin, Ting-Ting
    Wu, Yu-Peng
    Huang, Peng
    Ke, Zhi-Bin
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xue, Xue-Yi
    Lin, Rong-Jin
    Xu, Ning
    JOURNAL OF CANCER, 2021, 12 (04): : 1249 - 1257
  • [7] Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
    Marin-Aguilera, Mercedes
    Codony-Servat, Jordi
    Kalko, Susana G.
    Fernandez, Pedro L.
    Bermudo, Raquel
    Buxo, Elvira
    Jose Ribal, Maria
    Gascon, Pedro
    Mellado, Begona
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) : 329 - 339
  • [8] Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer
    Jochems, Caroline
    Boyerinas, Benjamin
    Madan, Ravi A.
    Poole, Diane J.
    Ning, Yang-Min
    Figg, William D.
    Liewehr, David J.
    Steinberg, Seth M.
    Gulley, James L.
    Tsang, Kwong-Yok
    Schlom, Jeffrey
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
    Lanka, Sree M.
    Zorko, Nicholas A.
    Antonarakis, Emmanuel S.
    Barata, Pedro C.
    CURRENT ONCOLOGY, 2023, 30 (04) : 4246 - 4256
  • [10] Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Smith, Thomas J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1175 - 1175